Background: The International Hip Outcome Tool 12 (iHOT12), which is now widely adopted in clinical settings, has been established as reliable, valid, and responsive, positioning as a critical evaluation tool globally to gauge the efficacy of hip arthroscopy.This study aimed to translate the iHOT12 questionnaire into Korean and assess its feasibility, internal consistency, and validity concerning the psychometric properties of the Korean version of iHOT12 (iHOT12-K). Methods: The iHOT12 questionnaire was translated into Korean and adapted culturally, following international guidelines, involving forward translation, back-translation, and reconciliation by bilingual experts to ensure cross-cultural equivalence. A cohort of 67 patients diagnosed with femoroacetabular impingement and scheduled for hip arthroscopy between November 2015 and February 2021 participated in assessing the psychometric properties of the iHOT12-K, alongside standardized questionnaires (Korean iterations of the Short Form-36 [SF-36], Hip Disability and Osteoarthritis Outcome Score [HOOS], Korean version of Hip Outcome Score [HOS-K], and modified Harris Hip Score [mHHS]). Psychometric evaluations focusing on feasibility, internal consistency (Cronbach's alpha), and convergent validity (Spearman’s rank correlation) demonstrated the reliability and relevance of iHOT12-K. Results: In the psychometric evaluation of the adapted version, 67 participants (38 men and 29 women; median age, 41 years) were enrolled, with 59 completing the iHOT12-K. The questionnaire showed excellent internal consistency (Cronbach’s alpha, 0.896) without floor or ceiling effects, indicating good feasibility. Strong convergent validity was noted between the iHOT12-K and various hip-specific questionnaires (HOOS, HOS-K, and mHHS), except for the maximal visual analog scale score, demonstrating the reliability and applicability of the iHOT12-K for clinical assessments in Korea. Conclusions The iHOT12-K has successfully undergone transcultural adaptation, demonstrating significant feasibility, internal consistency, and validity. It has been validated for use among Korean-speaking patients undergoing hip arthroscopy, proving to be a valuable tool for clinical assessments.

Background: The International Hip Outcome Tool 12 (iHOT12), which is now widely adopted in clinical settings, has been established as reliable, valid, and responsive, positioning as a critical evaluation tool globally to gauge the efficacy of hip arthroscopy.This study aimed to translate the iHOT12 questionnaire into Korean and assess its feasibility, internal consistency, and validity concerning the psychometric properties of the Korean version of iHOT12 (iHOT12-K). Methods: The iHOT12 questionnaire was translated into Korean and adapted culturally, following international guidelines, involving forward translation, back-translation, and reconciliation by bilingual experts to ensure cross-cultural equivalence. A cohort of 67 patients diagnosed with femoroacetabular impingement and scheduled for hip arthroscopy between November 2015 and February 2021 participated in assessing the psychometric properties of the iHOT12-K, alongside standardized questionnaires (Korean iterations of the Short Form-36 [SF-36], Hip Disability and Osteoarthritis Outcome Score [HOOS], Korean version of Hip Outcome Score [HOS-K], and modified Harris Hip Score [mHHS]). Psychometric evaluations focusing on feasibility, internal consistency (Cronbach's alpha), and convergent validity (Spearman’s rank correlation) demonstrated the reliability and relevance of iHOT12-K. Results: In the psychometric evaluation of the adapted version, 67 participants (38 men and 29 women; median age, 41 years) were enrolled, with 59 completing the iHOT12-K. The questionnaire showed excellent internal consistency (Cronbach’s alpha, 0.896) without floor or ceiling effects, indicating good feasibility. Strong convergent validity was noted between the iHOT12-K and various hip-specific questionnaires (HOOS, HOS-K, and mHHS), except for the maximal visual analog scale score, demonstrating the reliability and applicability of the iHOT12-K for clinical assessments in Korea. Conclusions The iHOT12-K has successfully undergone transcultural adaptation, demonstrating significant feasibility, internal consistency, and validity. It has been validated for use among Korean-speaking patients undergoing hip arthroscopy, proving to be a valuable tool for clinical assessments.

Background: The International Hip Outcome Tool 12 (iHOT12), which is now widely adopted in clinical settings, has been established as reliable, valid, and responsive, positioning as a critical evaluation tool globally to gauge the efficacy of hip arthroscopy.This study aimed to translate the iHOT12 questionnaire into Korean and assess its feasibility, internal consistency, and validity concerning the psychometric properties of the Korean version of iHOT12 (iHOT12-K). Methods: The iHOT12 questionnaire was translated into Korean and adapted culturally, following international guidelines, involving forward translation, back-translation, and reconciliation by bilingual experts to ensure cross-cultural equivalence. A cohort of 67 patients diagnosed with femoroacetabular impingement and scheduled for hip arthroscopy between November 2015 and February 2021 participated in assessing the psychometric properties of the iHOT12-K, alongside standardized questionnaires (Korean iterations of the Short Form-36 [SF-36], Hip Disability and Osteoarthritis Outcome Score [HOOS], Korean version of Hip Outcome Score [HOS-K], and modified Harris Hip Score [mHHS]). Psychometric evaluations focusing on feasibility, internal consistency (Cronbach's alpha), and convergent validity (Spearman’s rank correlation) demonstrated the reliability and relevance of iHOT12-K. Results: In the psychometric evaluation of the adapted version, 67 participants (38 men and 29 women; median age, 41 years) were enrolled, with 59 completing the iHOT12-K. The questionnaire showed excellent internal consistency (Cronbach’s alpha, 0.896) without floor or ceiling effects, indicating good feasibility. Strong convergent validity was noted between the iHOT12-K and various hip-specific questionnaires (HOOS, HOS-K, and mHHS), except for the maximal visual analog scale score, demonstrating the reliability and applicability of the iHOT12-K for clinical assessments in Korea. Conclusions The iHOT12-K has successfully undergone transcultural adaptation, demonstrating significant feasibility, internal consistency, and validity. It has been validated for use among Korean-speaking patients undergoing hip arthroscopy, proving to be a valuable tool for clinical assessments.

Background: The International Hip Outcome Tool 12 (iHOT12), which is now widely adopted in clinical settings, has been established as reliable, valid, and responsive, positioning as a critical evaluation tool globally to gauge the efficacy of hip arthroscopy.This study aimed to translate the iHOT12 questionnaire into Korean and assess its feasibility, internal consistency, and validity concerning the psychometric properties of the Korean version of iHOT12 (iHOT12-K). Methods: The iHOT12 questionnaire was translated into Korean and adapted culturally, following international guidelines, involving forward translation, back-translation, and reconciliation by bilingual experts to ensure cross-cultural equivalence. A cohort of 67 patients diagnosed with femoroacetabular impingement and scheduled for hip arthroscopy between November 2015 and February 2021 participated in assessing the psychometric properties of the iHOT12-K, alongside standardized questionnaires (Korean iterations of the Short Form-36 [SF-36], Hip Disability and Osteoarthritis Outcome Score [HOOS], Korean version of Hip Outcome Score [HOS-K], and modified Harris Hip Score [mHHS]). Psychometric evaluations focusing on feasibility, internal consistency (Cronbach's alpha), and convergent validity (Spearman’s rank correlation) demonstrated the reliability and relevance of iHOT12-K. Results: In the psychometric evaluation of the adapted version, 67 participants (38 men and 29 women; median age, 41 years) were enrolled, with 59 completing the iHOT12-K. The questionnaire showed excellent internal consistency (Cronbach’s alpha, 0.896) without floor or ceiling effects, indicating good feasibility. Strong convergent validity was noted between the iHOT12-K and various hip-specific questionnaires (HOOS, HOS-K, and mHHS), except for the maximal visual analog scale score, demonstrating the reliability and applicability of the iHOT12-K for clinical assessments in Korea. Conclusions The iHOT12-K has successfully undergone transcultural adaptation, demonstrating significant feasibility, internal consistency, and validity. It has been validated for use among Korean-speaking patients undergoing hip arthroscopy, proving to be a valuable tool for clinical assessments.

Dentin hypersensitivity is an abrupt intense pain caused by innocuous stimuli to exposed dentinal tubules. Mechanosensitive ion channels have been assessed in dental primary afferent neurons and odontoblasts to explain dentin hypersensitivity. Dentinal fluid dynamics evoked by various stimuli to exposed dentin cause mechanical stress to the structures underlying dentin. This review briefly discusses three hypotheses regarding dentin hypersensitivity and introduces recent findings on mechanosensitive ion channels expressed in the dental sensory system and discusses how the activation of these ion channels is involved in dentin hypersensitivity.
Dental Physiological Phenomena ; Dentin Sensitivity ; Dentin ; Dentinal Fluid ; Hydrodynamics ; Ion Channels ; Mechanoreceptors ; Neurons, Afferent ; Odontoblasts ; Stress, Mechanical

STUDY DESIGN: Prospective randomized noninferiority trial. PURPOSE: To evaluate whether the union rate of anterior cervical discectomy and fusion (ACDF) using a polyetheretherketone (PEEK) cage filled with a mixture of hydroxyapatite (HA) and demineralized bone matrix (DBM) is inferior to that of a mixture of beta-tricalcium phosphate (beta-TCP) and HA. OVERVIEW OF LITERATURE: There have been no clinical trials investigating the outcomes of a mixture of HA and DBM in a PEEK cage in ACDF. METHODS: Eighty-five eligible patients were randomly assigned to group B (n=43), in which a PEEK cage with a mixture of HA and DBM was used, or group C (n=42), in which a PEEK cage with a mixture of HA and beta-TCP was used. The primary study endpoint was the fusion rate, which was assessed with dynamic radiographs and computed tomography (CT) scans. Secondary endpoints included pain intensity using a visual analogue scale, functional outcome using a neck disability index score, laboratory tests of inflammatory profiles, and the infection rate. RESULTS: Seventy-seven patients (38 in group B and 39 in group C) were included in the final analysis. One year postoperatively, bone fusion was achieved in 87% of group B patients and 87% of group C patients on dynamic radiographs, and 87% of group B patients and 72% of group C patients on CT scans (p=1.00 and 0.16, respectively). There were also no between-groups differences with respect to the secondary endpoints. CONCLUSIONS: A HA/DBM mixture inside a PEEK cage can provide noninferior outcomes compared to a HA/TCP mixture in ACDF.
Bone Matrix* ; Diskectomy* ; Durapatite ; Humans ; Hydroxyapatites ; Neck ; Prospective Studies* ; Tomography, X-Ray Computed

Background: The clinical outcomes of delayed radioiodine remnant ablation (RRA) therapy in patients with low-risk papillary thyroid carcinoma (PTC) are unclear. We aimed to evaluate the clinical impact of the interval between total thyroidectomy (TT) and RRA therapy in patients with low-risk PTC. Methods: We included 526 patients who underwent TT and RRA for low-risk PTC with a primary tumor size of >1 cm between 2000 and 2012. Patients were divided into the early (<90 days) and the delayed (≥90 days) RRA groups based on the interval between TT and RRA. The results of diagnostic whole-body scan (DxWBS), ongoing risk stratification (ORS; response to therapy), and disease-free survival (DFS) were evaluated before and after propensity score matching (PSM). Results: Among the 526 patients, 75 (14.3%) patients underwent delayed RRA; they had more cervical lymph node metastasis and received a higher RRA dose than those who underwent early RRA. The median follow-up period was 9.1 years after initial therapy, and the structural recurrence rate was 1.9%. In DxWBS, 60 patients had focal iodine uptake limited in operative bed, with no significant difference between groups. According to ORS, 78%, 20%, 1%, and 1% patients were classified into excellent, indeterminate, biochemical incomplete, and structural incomplete response groups, respectively. There was no significant difference in ORS or DFS between groups before and after PSM. Conclusion The timing of the first RRA had no clinical impact in patients with low-risk PTC. Thus, the clinical decision for RRA can be determined >3 months after TT considering other prognostic factors.

BACKGROUND: Recently, there has been some controversy regarding the role of radioactive iodine (RAI) ablation in the treatment of low-risk differentiated thyroid carcinoma (DTC), especially papillary thyroid microcarcinoma (PTMC). This study aimed to compare quality of life (QoL) parameters between patients with PTMC who underwent total thyroidectomy (TT) alone and those who underwent TT with RAI ablation. METHODS: In this cross-sectional study, patients with PTMC who underwent TT with/without RAI remnant ablation were prospectively enrolled between June 2016 and October 2017. All patients completed three questionnaires: the 12-item short-form health survey (SF-12), thyroid cancer-specific quality of life (THYCA-QoL) questionnaire, and fear of progression (FoP) questionnaire. RESULTS: The TT and TT with RAI groups comprised 107 and 182 patients, respectively. The TT with RAI group had significantly lower serum thyrotropin (TSH) levels than the TT group. However, after matching for TSH levels between the groups (n=100 in both groups), there were no significant differences in baseline characteristics. According to the SF-12, the score for general health was significantly lower in the TT with RAI group than in the TT group (P=0.047). The THYCA-QoL also showed a significant difference in the “felt chilly” score between groups (P=0.023). No significant differences in FoP scores were observed between the groups. CONCLUSION Patients with PTMC who underwent TT with RAI ablation experienced more health-related problems than those managed with TT alone. These findings support the idea that RAI ablation should be carefully considered in patients with low-risk DTCs.

Background: The optimal dose of radioactive iodine (RAI) therapy for N1b papillary thyroid carcinoma (PTC) is controversial. We evaluated the clinical outcome of N1b PTC patients treated with either 100 or 150 mCi of RAI. Methods: We retrospectively analyzed N1b PTC patients who underwent total thyroidectomy and postoperative RAI therapy at a tertiary referral center between 2012 and 2017. As the baseline characteristics differed between treatment groups, we performed exact matching for various pathological factors according to RAI dose. We evaluated the response to therapy and recurrence-free survival (RFS) in the matched patients. Structural recurrent/persistent disease was defined as new structural disease detected after initial therapy, which was confirmed by cytology or pathology. Results: Of the total 436 patients, 37 (8.5%) received 100 mCi of RAI and 399 (91.5%) received 150 mCi of RAI. After an exact 1:3 matching, 34 patients in the 100 mCi group and 100 patients in the 150 mCi group remained. There was no significant difference in response to therapy between the groups in the matched population (P=0.63). An excellent response was achieved in 70.6% (n=24) of patients in the 100 mCi group and 76.0% (n=76) in the 150 mCi group. Two (5.9%) patients in the 100 mCi group and four (4.0%) in the 150 mCi group had recurrence and there was no significant difference in RFS between the groups in the matched population (P=0.351). Conclusion There were no differences in response to therapy and RFS in N1b PTC patients according to RAI dose.

Recent studies have shown that circulating microRNAs are a potential biomarker in various types of malignancies. The aim of this study was to investigate the feasibility of using serum exosomal microRNAs as novel serological biomarkers for hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We measured the serum exosomal microRNAs and serum circulating microRNAs in patients with CHB (n=20), liver cirrhosis (LC) (n=20) and HCC (n=20). Serum exosomal microRNA was extracted from 500 mul of serum using an Exosome RNA Isolation kit. The expression levels of microRNAs were quantified by real-time PCR. The expression levels of selected microRNAs were normalized to Caenorhabditis elegans microRNA (Cel-miR-39). The serum levels of exosomal miR-18a, miR-221, miR-222 and miR-224 were significantly higher in patients with HCC than those with CHB or LC (P<0.05). Further, the serum levels of exosomal miR-101, miR-106b, miR-122 and miR-195 were lower in patients with HCC than in patients with CHB (P=0.014, P<0.001, P<0.001 and P<0.001, respectively). There was no significant difference in the levels of miR-21 and miR-93 among the three groups. Additionally, the serum levels of circulating microRNAs showed a smaller difference between HCC and either CHB or LC. This study suggests that serum exosomal microRNAs may be used as novel serological biomarkers for HCC.
Adult ; Aged ; Biomarkers, Tumor/blood/genetics ; Carcinoma, Hepatocellular/blood/diagnosis/*genetics ; Exosomes/genetics ; Female ; Gene Expression Profiling ; Humans ; Liver/pathology ; Liver Neoplasms/blood/diagnosis/*genetics ; Male ; MicroRNAs/blood/*genetics ; Middle Aged